Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 797

1.

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, Chi KN.

Can Urol Assoc J. 2019 Oct;13(10):307-314. doi: 10.5489/cuaj.6136. No abstract available.

PMID:
31603409
2.

Comprehensive analysis of in-hospital delirium after major surgical oncology procedures.

Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Graefen M, Montorsi F, Saad F, Shariat SF, Schips L, Briganti A, Karakiewicz PI.

Can Urol Assoc J. 2019 Sep 27. doi: 10.5489/cuaj.6030. [Epub ahead of print]

PMID:
31599720
3.

The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder.

Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Tian Z, Shariat SF, Saad F, de Cobelli O, Karakiewicz PI.

J Surg Oncol. 2019 Sep 28. doi: 10.1002/jso.25717. [Epub ahead of print]

PMID:
31562831
4.

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.

Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A, Smith MR.

Ann Oncol. 2019 Sep 27. pii: mdz397. doi: 10.1093/annonc/mdz397. [Epub ahead of print]

PMID:
31560066
5.

Novel insights into the complex architecture of osteoporosis molecular genetics.

Saad FA.

Ann N Y Acad Sci. 2019 Sep 26. doi: 10.1111/nyas.14231. [Epub ahead of print] Review.

PMID:
31556133
6.

[Cerebral edema in sepsis: Case report].

Mouawad V, Moughabghab A, Chehab A, Saad F, Akiki S.

Presse Med. 2019 Sep;48(9):985-987. doi: 10.1016/j.lpm.2019.08.001. Epub 2019 Sep 20. French. No abstract available.

PMID:
31548119
7.

External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients.

Knipper S, Dzyuba-Negrean C, Palumbo C, Pecoraro A, Rosiello G, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Int Urol Nephrol. 2019 Sep 21. doi: 10.1007/s11255-019-02284-1. [Epub ahead of print]

PMID:
31542882
8.

Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.

Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein B, Saad F, Luo J, de Bono JS.

Eur Urol. 2019 Sep 18. pii: S0302-2838(19)30684-0. doi: 10.1016/j.eururo.2019.08.034. [Epub ahead of print]

PMID:
31542304
9.

Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy.

Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Aug 21. pii: S1558-7673(19)30258-7. doi: 10.1016/j.clgc.2019.08.009. [Epub ahead of print]

PMID:
31515197
10.

Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.

Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B.

Clin Cancer Res. 2019 Sep 11. pii: clincanres.1050.2019. doi: 10.1158/1078-0432.CCR-19-1050. [Epub ahead of print]

PMID:
31511295
11.

18F[AlF]-radiolabelled Peptides on the Automated Synthesis Platform: Translating the Laboratory Bench Work to Bedside.

Hassan H, Razak HRA, Saad FFA, Kumar V.

Malays J Med Sci. 2019 Jul;26(4):122-126. doi: 10.21315/mjms2019.26.4.14. Epub 2019 Aug 29.

12.

Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma.

Palumbo C, Mistretta FA, Knipper S, Mazzone E, Pecoraro A, Tian Z, Perrotte P, Antonelli A, Montorsi F, Shariat SF, Saad F, Simeone C, Briganti A, Lavallee LT, Karakiewicz PI.

Minerva Urol Nefrol. 2019 Sep 4. doi: 10.23736/S0393-2249.19.03496-9. [Epub ahead of print]

PMID:
31487976
13.

Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma.

Rosiello G, Knipper S, Palumbo C, Dzyuba-Negrean C, Pecoraro A, Mazzone E, Mistretta FA, Tian Z, Capitanio U, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Int Urol Nephrol. 2019 Aug 29. doi: 10.1007/s11255-019-02266-3. [Epub ahead of print]

PMID:
31468289
14.

Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis.

Mazzone E, Knipper S, Mistretta FA, Tian Z, Palumbo C, Soulieres D, De Cobelli O, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

World J Urol. 2019 Aug 28. doi: 10.1007/s00345-019-02927-z. [Epub ahead of print]

PMID:
31463562
15.

V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss.

Mohammad AH, Assadian S, Couture F, Lefebvre KJ, El-Assaad W, Barrès V, Ouellet V, Boulay PL, Yang J, Latour M, Furic L, Muller W, Sonenberg N, Mes-Masson AM, Saad F, Day R, Teodoro JG.

Oncotarget. 2019 Aug 13;10(48):4923-4936. doi: 10.18632/oncotarget.27075. eCollection 2019 Aug 13.

16.

Rubella seroprevalence and demographic feature analysis in pregnant women from Southern Pakistan.

Khan A, Rahman H, Noushin R, Anjum SI, Saad F, Ullah K.

J Pak Med Assoc. 2019 Aug;69(8):959-963.

17.

A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer.

Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Oct;17(5):395-401. doi: 10.1016/j.clgc.2019.07.008. Epub 2019 Jul 19.

PMID:
31416752
18.

The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.

Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Montorsi F, Graefen M, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Eur Urol Oncol. 2019 Sep;2(5):541-548. doi: 10.1016/j.euo.2018.10.010. Epub 2018 Nov 22.

PMID:
31411992
19.

Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.

Preisser F, Bandini M, Nazzani S, Mazzone E, Marchioni M, Tian Z, Chun FKH, Saad F, Briganti A, Haese A, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Oncol. 2019 Mar 28. pii: S2588-9311(19)30035-5. doi: 10.1016/j.euo.2019.03.003. [Epub ahead of print]

PMID:
31411975
20.

Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors.

Palumbo C, Mistretta FA, Mazzone E, Knipper S, Tian Z, Perrotte P, Antonelli A, Montorsi F, Shariat SF, Saad F, Simeone C, Briganti A, Lattouf JB, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Oct;17(5):e1026-e1035. doi: 10.1016/j.clgc.2019.06.003. Epub 2019 Jun 13.

PMID:
31378580
21.

Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer.

Preisser F, Nazzani S, Mazzone E, Marchioni M, Bandini M, Tian Z, Haese A, Saad F, Zorn K, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Oct;17(5):e939-e945. doi: 10.1016/j.clgc.2019.05.022. Epub 2019 May 27.

PMID:
31375352
22.

Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis.

Palumbo C, Pecoraro A, Knipper S, Rosiello G, Tian Z, Shariat SF, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI.

Anticancer Res. 2019 Aug;39(8):4357-4361. doi: 10.21873/anticanres.13604.

PMID:
31366530
23.

Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer.

Danielson B, Saad F, So A, Morgan S, Hamilton RJ, Malone S, Park-Wyllie L, Zardan A, Shayegan B.

Can Urol Assoc J. 2019 Feb 7. doi: 10.5489/cuaj.5600. [Epub ahead of print] Review.

PMID:
31364976
24.

Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?

Gómez Rivas J, Carrion DM, Alvarez-Maestro M, Cathelineau X, Sanchez-Salas R, Di Lorenzo G, Di Maio M, Paul A, Martinez-Piñeiro L, Sartor O, Saad F, Debruyne F.

Minerva Urol Nefrol. 2019 Jul 25. doi: 10.23736/S0393-2249.19.03420-9. [Epub ahead of print]

PMID:
31353876
25.

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).

Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North S, Pouliot F, Rendon R, Shayegan B, Sridhar S, So A, Usmani N, Vigneault E, Chi KN.

Can Urol Assoc J. 2019 Jun 25. doi: 10.5489/cuaj.6136. [Epub ahead of print] No abstract available.

PMID:
31348741
26.

In Patients with Nonmetastatic pT1b Kidney Cancer Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy.

Pecoraro A, Palumbo C, Knipper S, Mistretta FA, Tian Z, Shariat SF, Saad F, Briganti A, Fiori C, Porpiglia F, Karakiewicz PI.

J Urol. 2019 Jul 26:101097JU0000000000000460. doi: 10.1097/JU.0000000000000460. [Epub ahead of print]

PMID:
31347950
27.

Impact of Obesity on Perioperative Outcomes at Robotic-assisted and Open Radical Prostatectomy: Results From the National Inpatient Sample.

Knipper S, Mazzone E, Mistretta FA, Palumbo C, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Urology. 2019 Jul 20. pii: S0090-4295(19)30646-6. doi: 10.1016/j.urology.2019.05.053. [Epub ahead of print]

PMID:
31336110
28.

Continuing to improve outcomes of men with metastatic prostate cancer.

Saad F.

Nat Rev Clin Oncol. 2019 Oct;16(10):597-598. doi: 10.1038/s41571-019-0254-9. No abstract available.

PMID:
31312041
29.

Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.

Saad F, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Nilsson S, Miller K, Wirth M, Reeves J, Seger M, Carles J, Heidenreich A.

Clin Genitourin Cancer. 2019 Oct;17(5):348-355.e5. doi: 10.1016/j.clgc.2019.05.012. Epub 2019 May 31.

30.

Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality.

Mistretta FA, Palumbo C, Knipper S, Mazzone E, Pecoraro A, Tian Z, Musi G, Perrotte P, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI.

World J Urol. 2019 Jul 11. doi: 10.1007/s00345-019-02869-6. [Epub ahead of print]

PMID:
31297629
31.

How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder.

Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Shariat SF, Saad F, Simeone C, Briganti A, Antonelli A, Karakiewicz PI.

Urol Oncol. 2019 Jul 8. pii: S1078-1439(19)30220-0. doi: 10.1016/j.urolonc.2019.05.020. [Epub ahead of print]

PMID:
31296422
32.

Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates.

Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Tilki D, Musi G, Perrotte P, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI.

Urol Oncol. 2019 Sep;37(9):578.e11-578.e19. doi: 10.1016/j.urolonc.2019.05.024. Epub 2019 Jul 8.

PMID:
31296420
33.

Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.

Grosset AA, Ouellet V, Caron C, Fragoso G, Barrès V, Delvoye N, Latour M, Aprikian A, Bergeron A, Chevalier S, Fazli L, Fleshner N, Gleave M, Karakiewicz P, Lacombe L, Lattouf JB, van der Kwast T, Trudel D, Mes-Masson AM, Saad F; Canadian Prostate Cancer Biomarker Network.

PLoS Med. 2019 Jul 2;16(7):e1002847. doi: 10.1371/journal.pmed.1002847. eCollection 2019 Jul.

34.

Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients.

Palumbo C, Knipper S, Dzyuba-Negrean C, Pecoraro A, Rosiello G, Tian Z, Shariat SF, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI.

J Geriatr Oncol. 2019 Jun 27. pii: S1879-4068(19)30196-1. doi: 10.1016/j.jgo.2019.06.005. [Epub ahead of print]

PMID:
31257163
35.

CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis.

Dankner M, Ouellet V, Communal L, Schmitt E, Perkins D, Annis MG, Barrès V, Caron C, Mes-Masson AM, Saad F, Siegel PM; Canadian Prostate Cancer Biomarker Network.

Am J Pathol. 2019 Jul;189(7):1451-1461. doi: 10.1016/j.ajpath.2019.04.006. Epub 2019 Jun 12.

PMID:
31202437
36.

L'urologie au Canada - de nombreuses raisons d'être fiers.

Saad F.

Can Urol Assoc J. 2019 Jun;13(6):215. doi: 10.5489/cuaj.6056. No abstract available.

37.

Canadian urology - so much to be proud of.

Saad F.

Can Urol Assoc J. 2019 Jun;13(6):153. doi: 10.5489/cuaj.6045. No abstract available.

38.

Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy.

Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Lattouf JB, Musi G, Perrotte P, Montanari E, Shariat SF, Montorsi F, Saad F, de Cobelli O, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Aug;17(4):e793-e801. doi: 10.1016/j.clgc.2019.04.015. Epub 2019 Apr 30.

PMID:
31182339
39.

Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis.

Mazzone E, Mistretta FA, Knipper S, Palumbo C, Tian Z, Pecoraro A, Preisser F, Gallina A, Shariat SF, Saad F, Graefen M, Montorsi F, Briganti A, Karakiewicz PI.

BJU Int. 2019 May 30. doi: 10.1111/bju.14841. [Epub ahead of print]

PMID:
31144770
40.

CUA - Listening and learning how to best serve the urology community!

Saad F.

Can Urol Assoc J. 2019 Apr;13(4):81. doi: 10.5489/cuaj.5953. No abstract available.

41.

Contemporary clinicopathological characteristics of pT0 prostate cancer at radical prostatectomy: A population-based study.

Knipper S, Tilki D, Mazzone E, Mistretta FA, Palumbo C, Pecoraro A, Tian Z, Briganti A, Saad F, Graefen M, Karakiewicz PI.

Urol Oncol. 2019 Oct;37(10):696-701. doi: 10.1016/j.urolonc.2019.05.001. Epub 2019 May 22.

PMID:
31129038
42.

Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.

Slovin S, Hussain S, Saad F, Garcia J, Picus J, Ferraldeschi R, Crespo M, Flohr P, Riisnaes R, Lin C, Keer H, Oganesian A, Workman P, de Bono J.

Clin Cancer Res. 2019 Aug 1;25(15):4624-4633. doi: 10.1158/1078-0432.CCR-18-3212. Epub 2019 May 21.

PMID:
31113841
43.

Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study.

Knipper S, Preisser F, Mazzone E, Mistretta FA, Palumbo C, Tian Z, Briganti A, Shariat SF, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Urol Oncol. 2019 Oct;37(10):702-710. doi: 10.1016/j.urolonc.2019.04.023. Epub 2019 May 15.

PMID:
31103337
44.

The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.

Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Mazzone E, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Eur Urol Oncol. 2018 Aug;1(3):215-222. doi: 10.1016/j.euo.2018.03.007. Epub 2018 May 15.

PMID:
31102624
45.

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.

Bandini M, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, Shariat SF, Montorsi F, Saad F, Briganti A, Karakiewicz P.

Eur Urol Oncol. 2018 Sep;1(4):314-320. doi: 10.1016/j.euo.2018.04.013. Epub 2018 May 15.

PMID:
31100253
46.

Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy.

Zaffuto E, Bandini M, Moschini M, Leyh-Bannurah SR, Gazdovich S, Dell'Oglio P, Gallina A, Shariat SF, Briganti A, Montorsi F, Saad F, Karakiewicz PI.

Eur Urol Oncol. 2018 Jun;1(2):169-175. doi: 10.1016/j.euo.2018.02.001. Epub 2018 May 15.

PMID:
31100242
47.

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.

Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Saad F, Pompe RS, Briganti A, Budäus L, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Oncol. 2018 Jun;1(2):160-168. doi: 10.1016/j.euo.2018.03.006. Epub 2018 May 15.

PMID:
31100241
48.

Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study.

Knipper S, Preisser F, Mazzone E, Mistretta FA, Tian Z, Briganti A, Zorn KC, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Jun;17(3):231-237.e2. doi: 10.1016/j.clgc.2019.04.009. Epub 2019 Apr 16.

PMID:
31080021
49.

WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors.

Gaudreau PO, Clairefond S, Class CA, Boulay PL, Chrobak P, Allard B, Azzi F, Pommey S, Do KA, Saad F, Trudel D, Young M, Stagg J.

Oncoimmunology. 2019 Mar 22;8(5):e1581545. doi: 10.1080/2162402X.2019.1581545. eCollection 2019.

PMID:
31069142
50.

Management algorithms for metastatic prostate cancer.

Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So A, Park-Wyllie L, Hew H, McLeod D, Gotto G.

Can Urol Assoc J. 2019 Apr 26. doi: 10.5489/cuaj.5840. [Epub ahead of print] Review.

PMID:
31039111

Supplemental Content

Support Center